B cell expression of the inhibitory Fcγ receptor is unchanged in early MS

Journal of Neuroimmunology

Volumn 223, Issue 1-2, 2010, Pages 135-137

  Comabella, Manuel ^a   Montalban, Xavier ^a   Kakalacheva, Kristina ^b   Osman, Deeqa ^b   Nimmerjahn, Falk ^c   Tintoré, Mar ^a   Lünemann, Jan D ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoimmunity; B cell; Clinically isolated syndrome; Fc receptor; Multiple sclerosis

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; FC RECEPTOR IIB;

ADULT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEMORY CELL; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OPTIC NEURITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOMATOLOGY;

ADULT; B-LYMPHOCYTE SUBSETS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; GROWTH INHIBITORS; HUMANS; IMMUNE TOLERANCE; MALE; MULTIPLE SCLEROSIS; RECEPTORS, IGG; SYNDROME; TIME FACTORS; YOUNG ADULT;

EID: 77953545423     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.03.015     Document Type: Article

References (12)

1. Antel J., Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol. 2006, 180:3-8.
2. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., Waubant E., Gazda S., Fox R.J., Panzara M., Sarkar N., Agarwal S., Smith C.H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63:395-400.
3. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., Lyons J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2006, 180:63-70.
4. Dalakas M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 2008, 4:557-567.
5. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
6. Hemmer B., Archelos J.J., Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 2002, 3:291-301.
7. Mackay M., Stanevsky A., Wang T., Aranow C., Li M., Koenig S., Ravetch J.V., Diamond B. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J. Exp. Med. 2006, 203:2157-2164.
8. McFarland H.F. The B cell-old player, new position on the team. N. Engl. J. Med. 2008, 358:664-665.
9. Meffre E., Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr. Opin. Immunol. 2008, 20:632-638.
10. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
11. Qin Y., Duquette P. B-cell immunity in MS. Int. MS J. 2003, 10:110-120.
12. Tackenberg B., Jelcic I., Baerenwaldt A., Oertel W.H., Sommer N., Nimmerjahn F., Lunemann J.D. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4788-4792.